Which Antiplatelet Works Better in Impaired Renal Function?

TOPLINE:

Prasugrel provided a more rapid reduction in platelet aggregation than clopidogrel in patients with stable coronary artery disease on dual antiplatelet therapy and an impaired renal function, specifically within initial days of treatment initiation.

METHODOLOGY:

Chronic kidney disease often coexists with coronary artery disease and is known to impair drug metabolism. Whether renal function affects platelet aggregation induced by commonly used antiplatelet drugs remains unclear.

Researchers conducted a substudy of a previous prospective trial involving 164 patients with stable coronary artery disease (median age, 67 years; 82.9% men) who were receiving dual antiplatelet therapy with aspirin and clopidogrel.

Patients were randomly assigned to either continue 75 mg of clopidogre